Zobrazeno 1 - 10
of 110
pro vyhledávání: ''
Publikováno v:
Cancer chemotherapy and pharmacology
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Panitumumab is a human monoclonal antibody targeting the epidermal growth factor receptor for the treatment of wild-type RAS metastatic colorectal cancer (mCRC). Currently, no dedicated clinical studies have evaluated the effect of organ impa
Autor:
Karim A. Benhadji, Lee S. Rosen, Muhammad Wasif Saif, Smitha S. Krishnamurthi, Carlos Becerra, Thomas J. George, Weijing Sun, Vladimir Sramek, Marwan Fakih, Bojan Zaric, Ikuo Yamamiya, Jiri Skopek, Yaohua He, Kensuke Hamada, Michelle A. Rudek, Lazar Popovic, Dale R. Shepard
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:485-497
Trifluridine/tipiracil (FTD/TPI) is approved for advanced colorectal and gastric/gastroesophageal cancer; however, data in patients with renal impairment (RI) are limited. This phase I study evaluated FTD/TPI in patients with advanced solid tumors an
Autor:
Yuhki Sakuraoka, Shozo Mori, Takayuki Shiraki, Yukihiro Iso, Takatsugu Matsumoto, Keiichi Kubota, Takamune Yamaguchi, Takayuki Shimizu, Kyung Hwa Park, Taku Aoki
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:109-120
Recently, the number of patients with pancreatic ductal adenocarcinoma (PDAC) who have received both neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) has been increasing. However, whether adverse events (AEs) during AC influence the prog
Autor:
Jonathan Cornu, Vu H. Duong, Alison Duffy, Maria R. Baer, Sandrine Niyongere, Jummai Apata, Ciera L Patzke, Noa G. Holtzman, Sarah M. Kashanian, Ashkan Emadi, Farin Kamangar, Madhurima Koka
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:817-826
Asparaginases, key agents in treatment of acute lymphoblastic leukemia (ALL), are associated with venous thromboembolism (VTE). While risks of short-acting asparaginase-related VTE is well-known, we studied VTE incidence and risk factors in adult ALL
Autor:
Keiichiro Ishibashi, Masahito Kotaka, Toru Aoyama, Yasushi Tsuji, Naoki Nagata, Hironaga Satake, Junichi Sakamoto, Masato Nakamura, Koji Oba, Masato Kataoka, Hideyuki Mishima
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background The aim of this study was to evaluate the efficacy and safety of first-line chemotherapy with re-introduction of oxaliplatin (OX) more than 6 months after adjuvant chemotherapy including OX. Methods Stage II/III colon cancer patients with
Autor:
Kaito Shibata, Junichi Kawakami, Satoshi Hirakawa, Hiroyuki Mineta, Seiji Hosokawa, Koji Suzuki, Takafumi Naito
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87(4):555-565
Purpose: Cetuximab inhibits epidermal growth factor receptor (EGFR) signaling in cancer and skin cells, thereby inducing anti-cancer effects and skin disorders. The present study aimed to evaluate the relationships between serum cetuximab and EGFR-re
Autor:
Qingtang Lin, Guoguang Zhao, Lan Zhang, Xinxia Li, Xiaobao Chen, Chaoying Hu, Chuan Liu, Jacqueline Ming Liu
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:793-801
Temozolomide is an alkylating agent approved by the U.S. Food and Drug Administration in 1999 for the treatment of patients with primary brain tumors. The aim of this study was to confirm the bioequivalence and safety of two strengths (20–100 mg) o
Autor:
Takashi Kojima, Satoshi Fujii, Hiroyuki Daiko, Hisanaga Nomura, Tomonori Yano, Toshikatsu Kawasaki, Ken Demachi, Nobuo Mochizuki, Daiki Tsuji, Haruki Matsuzawa, Kunihiko Itoh
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:315-324
The combination of docetaxel, cisplatin and 5-fluorouracil (DCF) is a newly developed chemotherapy regimen for esophageal cancer. Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chem
Autor:
Hiroya Iida, Sachiko Tanaka-Mizuno, Akira Andoh, Takehide Fujimoto, Rie Osaki, Daiki Hira, Satoshi Noda, Masaji Tani, Yoshito Ikeda, Tomohiro Terada, Shin-ya Morita
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:129-139
Purpose:Severe adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharma
Autor:
Gerald W. Prager, Andreas Schmiderer, Klaus Wilthoner, Angela Djanani, Matthias Unseld, Hossein Taghizadeh, Dieter Buchinger
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background Therapeutic options are limited for advanced, metastatic biliary tract cancer. The pivotal NAPOLI-1 trial demonstrated the superior clinical benefit of nanoliposomal irinotecan (Nal-IRI) in gemcitabine-pretreated patients with metastatic p